Cargando…
Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group
Patients with advanced-stage natural killer/T-cell lymphoma (NKTCL) usually have a poor prognosis. However, there is limited data of comprehensive analysis on this particular patient population due to the rarity of the disease. The present study aimed to investigate the treatment models, survival ou...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945040/ https://www.ncbi.nlm.nih.gov/pubmed/33718104 http://dx.doi.org/10.3389/fonc.2020.583050 |
_version_ | 1783662786079883264 |
---|---|
author | Liu, Weiping Yang, Yong Qi, Shunan Wang, Ying He, Xia Zhang, Liling Qu, Baolin Qian, Liting Hou, Xiaorong Qiao, Xueying Wang, Hua Li, Gaofeng Zhang, Yujing Zhu, Yuan Cao, Jianzhong Wu, Junxin Wu, Tao Zhu, Suyu Shi, Mei Xu, Liming Su, Hang Lin, Ningjing Zhu, Jun Li, Yexiong Song, Yuqin |
author_facet | Liu, Weiping Yang, Yong Qi, Shunan Wang, Ying He, Xia Zhang, Liling Qu, Baolin Qian, Liting Hou, Xiaorong Qiao, Xueying Wang, Hua Li, Gaofeng Zhang, Yujing Zhu, Yuan Cao, Jianzhong Wu, Junxin Wu, Tao Zhu, Suyu Shi, Mei Xu, Liming Su, Hang Lin, Ningjing Zhu, Jun Li, Yexiong Song, Yuqin |
author_sort | Liu, Weiping |
collection | PubMed |
description | Patients with advanced-stage natural killer/T-cell lymphoma (NKTCL) usually have a poor prognosis. However, there is limited data of comprehensive analysis on this particular patient population due to the rarity of the disease. The present study aimed to investigate the treatment models, survival outcomes, and prognosis of advanced-stage NKTCL. Data from 336 patients with advanced-stage NKTCL diagnosed between 2006 and 2015 in the China Lymphoma Collaborative Group database were retrospectively analyzed. The median age was 42 years and the male/female ratio was 2.4:1. About 97% of patients had stage IV disease and 77% had >1 extranodal involvement site. All patients received chemotherapy, with the most common option being asparaginase (Asp)-containing regimens (n=146; 43.5%). Among 286 patients with available response data, the overall response rate (ORR) was 57.3% with a complete remission (CR) rate of 35.7%. Asp-containing regimens led to better ORRs (86/132, 65.2% vs. 54/113, 47.8%, P = 0.006) and CR rates (60/132, 45.5% vs. 27/113, 23.9%, P < 0.001) than non-Asp-containing regimens. The expected 5-year progression-free survival (PFS) and overall survival (OS) rates were 22.6 and 32.0%, respectively, for the whole cohort. Compared to non-Asp-containing chemotherapy, Asp-containing chemotherapy improved 5-year PFS (34.2 vs. 17.1%, P < 0.001) and OS (45.3 vs. 27.8%, P < 0.001). A trend toward improvement in OS was observed when gemcitabine was added to Asp-containing chemotherapies. Moreover, those undergoing autologous hematopoietic stem cell transplantation had prolonged survival time. In conclusion, Asp-containing chemotherapy could improve the prognosis of advanced-stage NKTCL, and refinement of treatment models is warranted in the future. |
format | Online Article Text |
id | pubmed-7945040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79450402021-03-11 Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group Liu, Weiping Yang, Yong Qi, Shunan Wang, Ying He, Xia Zhang, Liling Qu, Baolin Qian, Liting Hou, Xiaorong Qiao, Xueying Wang, Hua Li, Gaofeng Zhang, Yujing Zhu, Yuan Cao, Jianzhong Wu, Junxin Wu, Tao Zhu, Suyu Shi, Mei Xu, Liming Su, Hang Lin, Ningjing Zhu, Jun Li, Yexiong Song, Yuqin Front Oncol Oncology Patients with advanced-stage natural killer/T-cell lymphoma (NKTCL) usually have a poor prognosis. However, there is limited data of comprehensive analysis on this particular patient population due to the rarity of the disease. The present study aimed to investigate the treatment models, survival outcomes, and prognosis of advanced-stage NKTCL. Data from 336 patients with advanced-stage NKTCL diagnosed between 2006 and 2015 in the China Lymphoma Collaborative Group database were retrospectively analyzed. The median age was 42 years and the male/female ratio was 2.4:1. About 97% of patients had stage IV disease and 77% had >1 extranodal involvement site. All patients received chemotherapy, with the most common option being asparaginase (Asp)-containing regimens (n=146; 43.5%). Among 286 patients with available response data, the overall response rate (ORR) was 57.3% with a complete remission (CR) rate of 35.7%. Asp-containing regimens led to better ORRs (86/132, 65.2% vs. 54/113, 47.8%, P = 0.006) and CR rates (60/132, 45.5% vs. 27/113, 23.9%, P < 0.001) than non-Asp-containing regimens. The expected 5-year progression-free survival (PFS) and overall survival (OS) rates were 22.6 and 32.0%, respectively, for the whole cohort. Compared to non-Asp-containing chemotherapy, Asp-containing chemotherapy improved 5-year PFS (34.2 vs. 17.1%, P < 0.001) and OS (45.3 vs. 27.8%, P < 0.001). A trend toward improvement in OS was observed when gemcitabine was added to Asp-containing chemotherapies. Moreover, those undergoing autologous hematopoietic stem cell transplantation had prolonged survival time. In conclusion, Asp-containing chemotherapy could improve the prognosis of advanced-stage NKTCL, and refinement of treatment models is warranted in the future. Frontiers Media S.A. 2021-02-19 /pmc/articles/PMC7945040/ /pubmed/33718104 http://dx.doi.org/10.3389/fonc.2020.583050 Text en Copyright © 2021 Liu, Yang, Qi, Wang, He, Zhang, Qu, Qian, Hou, Qiao, Wang, Li, Zhang, Zhu, Cao, Wu, Wu, Zhu, Shi, Xu, Su, Lin, Zhu, Li and Song http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Liu, Weiping Yang, Yong Qi, Shunan Wang, Ying He, Xia Zhang, Liling Qu, Baolin Qian, Liting Hou, Xiaorong Qiao, Xueying Wang, Hua Li, Gaofeng Zhang, Yujing Zhu, Yuan Cao, Jianzhong Wu, Junxin Wu, Tao Zhu, Suyu Shi, Mei Xu, Liming Su, Hang Lin, Ningjing Zhu, Jun Li, Yexiong Song, Yuqin Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group |
title | Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group |
title_full | Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group |
title_fullStr | Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group |
title_full_unstemmed | Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group |
title_short | Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group |
title_sort | treatment, survival, and prognosis of advanced-stage natural killer/t-cell lymphoma: an analysis from the china lymphoma collaborative group |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945040/ https://www.ncbi.nlm.nih.gov/pubmed/33718104 http://dx.doi.org/10.3389/fonc.2020.583050 |
work_keys_str_mv | AT liuweiping treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT yangyong treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT qishunan treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT wangying treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT hexia treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT zhangliling treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT qubaolin treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT qianliting treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT houxiaorong treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT qiaoxueying treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT wanghua treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT ligaofeng treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT zhangyujing treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT zhuyuan treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT caojianzhong treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT wujunxin treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT wutao treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT zhusuyu treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT shimei treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT xuliming treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT suhang treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT linningjing treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT zhujun treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT liyexiong treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup AT songyuqin treatmentsurvivalandprognosisofadvancedstagenaturalkillertcelllymphomaananalysisfromthechinalymphomacollaborativegroup |